Peptides for Fibromyalgia: What the Research Shows

Key Takeaways

• Compounds covered: BPC-157, thymosin alpha-1 (thymalfasin)
• Goal area: Chronic widespread pain management and neuroinflammatory modulation
• Evidence range: Animal studies and indirect clinical data only — no compound has completed a randomized controlled trial specifically for fibromyalgia
• Regulatory range: Both BPC-157 and thymosin alpha-1 are classified by FDA as §503A Category 2 bulk drug substances — compounding from bulk is not covered by FDA's enforcement discretion. Neither is FDA-approved for fibromyalgia or any pain indication; no peptide is FDA-approved for fibromyalgia.
• Key biomarkers for fibromyalgia evaluation: hs-CRP, CBC, thyroid panel (TSH, free T3), comprehensive metabolic panel, vitamin D, ferritin
• As of April 2026: Both BPC-157 and thymosin alpha-1 are classified by FDA as §503A Category 2 bulk drug substances — compounding from bulk is not covered by FDA's enforcement discretion under Section 503A. Neither is FDA-approved for fibromyalgia or any pain indication in the United States.
• Bottom line: No peptide has clinical trial evidence for fibromyalgia. Research is mechanistically suggestive but not clinically established.

Understanding Fibromyalgia: The Biology

Fibromyalgia is a chronic widespread pain condition characterized by amplified pain processing, fatigue, cognitive dysfunction, and sleep disturbance. Jurado-Priego and colleagues, writing in Biomedicines in 2024, provided a review of fibromyalgia pathophysiology, describing a multifactorial syndrome driven by alterations in central and peripheral nervous system pain processing rather than by measurable peripheral tissue damage. The condition does not fit neatly into classic inflammatory disease categories, which is what makes both its treatment and its research so challenging.

The central mechanism is sensitization of the pain-processing system. Ji and colleagues, reviewing neuroinflammation and chronic pain in Anesthesiology in 2018, described how neuroinflammatory processes amplify nociceptive signaling, producing allodynia and hyperalgesia that extend beyond the initial site of any injury. In fibromyalgia, this sensitization becomes generalized. Endogenous peptides including substance P, calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide are among the signaling molecules involved in maintaining this sensitized state. Latremoliere and Woolf, in their foundational 2009 review in the Journal of Pain, central sensitization generates pain hypersensitivity — a framework central to how contemporary research situates peptidergic modulation of pain signaling.

The immune dimension is present but contested. Findeisen and colleagues, writing in Brain Sciences in 2025, reviewed neuroinflammatory aspects of fibromyalgia, noting that small fiber neuropathy, mast cell activation, and low-level glial activation have been described in subsets of fibromyalgia patients and may contribute to the syndrome, though these findings have not been consistently replicated. Ryabkova and colleagues, writing in the International Journal of Molecular Sciences in 2019, reviewed autoimmune and neuroinflammatory mechanisms in fibromyalgia, supporting a neuroinflammatory hypothesis in a subset of patients. Di Franco and colleagues, writing in Annals of the New York Academy of Sciences in 2010, described HPA axis dysregulation in fibromyalgia consistent with a systemic neuroendocrine–immune disruption. These findings describe the neuroinflammatory context in which immunomodulatory peptides have been studied mechanistically, though no peptide has completed a clinical trial for fibromyalgia.

Peptides Studied in Fibromyalgia-Adjacent Contexts: A Quick Comparison

No peptide has published evidence from a clinical trial with fibromyalgia as the primary endpoint. The following compounds have evidence in mechanisms or conditions with relevant biological overlap. They are listed here for educational context only.

• Compound: BPC-157
  Mechanism relevant to fibromyalgia: Anti-inflammatory effects in animal models; modulation of dopaminergic and serotonergic signaling; CNS pain-pathway modulation in preclinical work
  Evidence: Animal studies only; no completed human trial for fibromyalgia or any chronic pain condition
  FDA status: Not FDA-approved for any indication; FDA §503A Category 2 bulk drug substance as of April 2026 — compounding from bulk is not covered by FDA's enforcement discretion under Section 503A
  SP availability: Not available through Superpower
• Compound: Thymosin alpha-1 (thymalfasin)
  Mechanism relevant to fibromyalgia: Immunomodulation via T-cell maturation and cytokine regulation; reduced inflammatory pain via Wnt3a/beta-catenin pathway modulation in spinal cord (mouse model)
  Evidence: Preclinical (mouse model for pain); clinical trials in immune and infectious disease contexts only — none for fibromyalgia
  FDA status: Not FDA-approved for fibromyalgia, any pain indication, or any indication in the United States. FDA §503A Category 2 bulk drug substance — compounding from bulk is not covered by FDA's enforcement discretion
  SP availability: Not available through Superpower for this use

Compounds listed as research-only or without FDA approval for the discussed use have not completed the clinical trial process required for regulatory authorization. Their inclusion here is for educational context only.

Peptides Studied in Fibromyalgia-Adjacent Contexts: Individual Profiles

Each compound is reviewed separately because the mechanisms differ, the evidence bases differ, and the regulatory statuses differ. Neither constitutes an established clinical option for fibromyalgia as of April 2026.

BPC-157

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid sequence — derived from a protective protein found in gastric juice. As of April 2026 it is classified by FDA as a §503A Category 2 bulk drug substance, which means FDA has identified safety concerns and/or insufficient information, and compounding from bulk BPC-157 is not covered by FDA's enforcement discretion under §503A.

The proposed mechanisms relevant to fibromyalgia-adjacent conditions include anti-inflammatory effects, modulation of the dopaminergic and serotonergic systems, and CNS pain-pathway activity. Sikiric and colleagues, writing in the Journal of Physiology and Pharmacology in 2009, described anti-inflammatory effects in a periodontitis model in preclinical work. A companion study published in Regulatory Peptides in 2010 by Sikiric and colleagues described BPC-157 effects on nerve injury recovery in preclinical models. A 2022 review in Neural Regeneration Research by Sikiric and colleagues reviewed BPC-157's CNS activity including pain signaling modulation.

A 2025 comprehensive review by Jozwiak and colleagues in Pharmaceuticals catalogued BPC-157's preclinical profile across multiple organ systems. Gonzalez-Torres and colleagues, publishing a systematic review in HSS Journal in 2025, reviewed BPC-157 in orthopaedic sports medicine and identified a consistent preclinical signal for tissue repair and anti-inflammatory activity alongside a near-complete absence of human clinical trial data.

Hines and colleagues, writing in Arthroscopy in 2024, reviewed injectable peptides in musculoskeletal rehabilitation, noting that BPC-157 appears in clinical discussions despite lacking controlled human trials. Stone and colleagues, in the American Journal of Sports Medicine in 2026, published an orthopaedic primer on peptide therapy, framing BPC-157 as an emerging area warranting formal clinical trial development before clinical adoption.

[Animal study — no human randomized controlled trial for fibromyalgia or chronic pain]

BPC-157 is not FDA-approved for any medical use. It is not available through Superpower or any licensed prescriber for fibromyalgia. Research is limited to animal and in vitro studies. Safety, efficacy, appropriate dosing, and long-term effects in humans have not been established for fibromyalgia or any related pain condition.

Thymosin alpha-1

Thymosin alpha-1 (thymalfasin; Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue. It functions as an immunomodulator, primarily promoting T-cell maturation and regulating cytokine networks. It is approved in several countries outside the United States for chronic hepatitis B and immunocompromise. In the United States, thymosin alpha-1 is not FDA-approved for any indication and is classified by FDA as a §503A Category 2 bulk drug substance — meaning compounding from bulk thymosin alpha-1 is not covered by FDA's enforcement discretion under Section 503A. It is not FDA-approved for fibromyalgia or any pain indication.

The rationale for its relevance to fibromyalgia is indirect. Camerini and colleagues, writing in Vitamins and Hormones in 2016, described thymosin alpha-1 and immune dysregulation of the type observed in a subset of fibromyalgia patients. Romani and colleagues, in the Annals of the New York Academy of Sciences in 2007, positioned thymosin alpha-1 as an endogenous regulator of inflammation and immunity — relevant given the immune-tolerance abnormalities documented in some fibromyalgia presentations.

The most directly relevant study is by Huang and colleagues, published in Neuroreport in 2020. In a mouse model of inflammatory pain, thymosin alpha-1 attenuated pain via Wnt3a/beta-catenin pathway in the spinal cord and was associated with reduced spinal markers of neuroinflammation and central sensitization in that study. This finding has not been replicated in human trials and is from an animal model, not a fibromyalgia clinical trial.

Dinetz and Lee, publishing a comprehensive review of thymosin alpha-1 safety and efficacy across human clinical trials in Alternative Therapies in Health and Medicine in 2024, documented a safety profile across disease contexts. Mensah and colleagues, reviewing chronic fatigue syndrome and immune dysfunction in Neurophysiologie Clinique in 2017, highlighted immune involvement in overlapping conditions sharing features with fibromyalgia.

[Animal study for pain indication; Phase II/III clinical trials in non-fibromyalgia immune contexts]

Thymosin alpha-1 is not FDA-approved for fibromyalgia or any pain indication in the United States. Its use for fibromyalgia has not been approved by the FDA. The safety and efficacy for this use have not been established through adequate and well-controlled clinical trials. It is not available through Superpower for this use.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry the following regulatory statuses.

• BPC-157: Not FDA-approved for any indication. Classified by FDA as a §503A Category 2 bulk drug substance — meaning FDA has identified safety concerns and/or insufficient information, and compounding from bulk BPC-157 is not covered by FDA's enforcement discretion under §503A. Research-only; not a lawful US compounding pathway for fibromyalgia.
• Thymosin alpha-1: Not FDA-approved for any indication in the United States. Placed by FDA on the §503A Category 2 bulk drug substances list — meaning FDA has identified safety concerns and/or insufficient information and compounding from bulk thymosin alpha-1 is not covered by FDA's enforcement discretion. Not routinely available through US compounding pharmacies; not available through Superpower for fibromyalgia.

Compounds listed as research-only or without FDA approval for the discussed use are not legal to prescribe or compound for fibromyalgia or chronic pain indications in the United States. Their presence in this article is for educational context only.

Considerations When Evaluating Peptides for Fibromyalgia

Direct comparison between these compounds is not straightforward — they have been studied in different models, using different endpoints, and against different disease contexts. Inferring clinical equivalence from separate preclinical studies is methodologically unreliable. A licensed provider evaluating a fibromyalgia patient for adjunctive therapies would approach the question through several clinical lenses.

The central sensitization mechanism versus peripheral inflammation: Fibromyalgia is primarily a central sensitization condition, not a peripheral inflammatory disease. A compound with primarily anti-inflammatory effects in peripheral tissues addresses only a subset of the biological picture. Compounds with demonstrated neuromodulatory activity are mechanistically more relevant to the core fibromyalgia pathophysiology — and the evidence for any peptide in that category is still preclinical.

Immune dysregulation in fibromyalgia is heterogeneous: Not all fibromyalgia patients show the same immune profile. Ryabkova and colleagues noted that small fiber neuropathy and neuroinflammatory markers are present in some patients but absent in others. An immunomodulatory peptide may be more or less relevant depending on an individual patient's inflammatory and immune picture — which requires biomarker assessment to characterize.

Evidence level and regulatory status: Both compounds reviewed here carry only preclinical evidence for pain-relevant endpoints. Your provider will weigh this carefully. A compound with animal data for a pain-adjacent mechanism is not the same as a compound with Phase II human trial data for fibromyalgia.

Existing treatment context: Fibromyalgia has three FDA-approved pharmacological treatments (duloxetine, milnacipran, pregabalin) along with non-pharmacological approaches (exercise, cognitive behavioral therapy) with the strongest evidence base. Any provider conversation about adjunctive peptide therapy would take place within that established treatment landscape.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety profiles for the compounds discussed here differ substantially from each other and from FDA-approved fibromyalgia medications. No blanket safety statement applies across this category.

Mendias and colleagues, reviewing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance in Sports Medicine in 2026, addressed safety and efficacy considerations for approved and unapproved peptide therapies in the musculoskeletal and athletic-performance setting — a scoping caveat that generalizes to fibromyalgia-context use where no controlled trial data exists — and noted that unapproved compounds lack the manufacturing oversight and clinical trial safety database present in approved products. For BPC-157 specifically, no long-term human safety data exist; all safety characterization is from animal studies and individual case reports. For thymosin alpha-1, a clinical trial safety database exists across non-fibromyalgia indications, but this does not establish the safety profile for pain applications or in fibromyalgia-specific populations.

Contraindications that apply broadly to investigational peptide therapy in a fibromyalgia context include:

• Pregnancy — no reproductive safety data exist for either compound in the context of fibromyalgia management
• Active autoimmune disease requiring immunosuppression — thymosin alpha-1 is immunostimulatory; interactions with immunosuppressive protocols are not well characterized
• Active malignancy — compounds with immune modulatory or growth factor-related properties carry theoretical proliferative concerns requiring clinician evaluation
• Products obtained outside regulated channels — because neither BPC-157 nor thymosin alpha-1 is routinely available through a lawful US compounding pathway, products marketed under these names online operate entirely outside FDA or USP manufacturing oversight; contamination, dosing inconsistency, and peptide misidentification risks are documented in seized preparations

For compound-specific side effect profiles, consult a licensed provider and reference FDA safety communications for any compound under consideration.

What to Test Before Exploring Peptide Therapy for Fibromyalgia

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether any intervention is producing the expected physiological changes — or whether those changes are beneficial. This principle applies with particular force in fibromyalgia, where symptom fluctuation is intrinsic to the condition and confounders are plentiful.

• hs-CRP (high-sensitivity C-reactive protein): Measures systemic low-grade inflammation. While peripheral inflammation is not consistently elevated in fibromyalgia, hs-CRP testing establishes whether an inflammatory component is present before attributing symptoms to central sensitization alone.
• Thyroid panel (TSH, free T3): Hypothyroidism produces fatigue, widespread pain, and cognitive symptoms that are clinically indistinguishable from fibromyalgia. Ruling out thyroid dysfunction is a prerequisite for any fibromyalgia intervention evaluation.
• CBC (complete blood count): Rules out anemia and characterizes immune cell populations. Baseline immune context is relevant if immunomodulatory compounds are being considered.
• Comprehensive metabolic panel (CMP): Liver and kidney function establish the safety baseline for any injectable compound. ALT and AST reflect hepatic function; eGFR reflects renal function and peptide clearance capacity.
• Vitamin D (25-hydroxyvitamin D): Vitamin D deficiency is associated with widespread pain and fatigue. Correcting deficiency before attributing symptoms to fibromyalgia pathophysiology alone is clinically appropriate.
• Ferritin: Iron deficiency can produce fatigue, pain sensitivity, and sleep disturbance overlapping with fibromyalgia presentations. Ferritin is the most sensitive available marker for iron depletion.
• IGF-1: If any GH-related compound is being considered alongside immune-modulating peptides, a baseline IGF-1 level characterizes the growth hormone axis and establishes the reference point for any subsequent change.

Thyroid function, hs-CRP, CBC, comprehensive metabolic panel, vitamin D, and ferritin are the most directly relevant baseline markers for anyone with a fibromyalgia diagnosis exploring any adjunctive intervention. These values rule out treatable contributors to the symptom picture and establish the biological context your provider needs to evaluate any therapeutic option objectively.

How to Access These Peptides Safely

Neither BPC-157 nor thymosin alpha-1 is FDA-approved for fibromyalgia or any indication in the United States. Both are classified by FDA as §503A Category 2 bulk drug substances, meaning compounding from bulk is not covered by FDA's enforcement discretion under Section 503A. There is no lawful US compounding pathway for either compound — for fibromyalgia or any other indication. Products sold as BPC-157 or thymosin alpha-1 online operate outside pharmaceutical manufacturing oversight.

Thymosin alpha-1 has a clinical history in immune contexts outside the United States but is not FDA-approved for any indication in the US. FDA placed thymosin alpha-1 on the §503A Category 2 bulks list, which means compounding from bulk substance is not covered by FDA's enforcement discretion. There is no lawful US compounding pathway for thymosin alpha-1 for fibromyalgia, and no clinical evidence supports this use.

Any clinical conversation about peptide therapy requires a thorough provider evaluation: complete health history, current medication review, baseline laboratory workup, and an informed discussion of the evidence base and regulatory status for each compound under consideration. Self-directed use of injectable compounds obtained without a prescription creates dosing uncertainty, contamination risk, and the inability to assess or monitor any biological changes.

Understanding Your Baseline

With fibromyalgia, the gap between the biological complexity of the condition and the available treatment options is real. Peptide research addresses some of the mechanisms involved — neuroinflammation, central sensitization, immune dysregulation — but has not yet produced clinical trial evidence for any compound in this context. What a comprehensive biomarker baseline does provide is the clearest picture of what is actually driving your symptom picture: whether there is an inflammatory component, a thyroid contribution, a nutritional deficiency, or a combination that predates the conversation about any specific compound.

That principle — objective data before intervention decisions — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to an FDA-approved fibromyalgia medication, a non-pharmacological approach, or a discussion of emerging compounds, the starting point is the same: knowing where your biomarkers stand.

Important Safety Information

BPC-157 is not approved by the FDA for any medical use. As of April 2026, BPC-157 is classified as an FDA Category 2 bulk drug substance; compounding under Section 503A is restricted pending further FDA review. Research on BPC-157 has been limited to laboratory and animal studies, with no completed human clinical trials for fibromyalgia or any chronic pain condition. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Thymosin alpha-1 is not FDA-approved for fibromyalgia or any pain indication in the United States. FDA placed thymosin alpha-1 on the §503A Category 2 bulk drug substances list; compounding from bulk thymosin alpha-1 is not covered by FDA's enforcement discretion. Evidence for thymosin alpha-1 in pain-relevant contexts is from a single animal model study. Clinical trial safety data for thymosin alpha-1 exist from immune and infectious disease contexts but do not establish a safety or efficacy profile for fibromyalgia. Thymosin alpha-1 is not available through Superpower for fibromyalgia or pain indications. Any use for fibromyalgia would be off-label and unsupported by clinical trial evidence. Always consult a licensed healthcare provider before initiating any peptide therapy.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide compounds with different regulatory statuses. Some compounds discussed are not approved for human use. BPC-157 is an FDA Category 2 bulk drug substance (compounding restricted). Thymosin alpha-1 is not FDA-approved for fibromyalgia. Superpower Health does not facilitate access to compounds discussed for fibromyalgia use. This educational content is editorially independent.